In addition, SAS, which is a clinical drug and a ferroptosis inducer, can effectively inhibit the growth of DLBCL by suppressing the expression of SLC7A11 (a component of system XC−) 78, further indicating the important role of ferroptosis in the regulation of DLBCL growth. The gene discussed is SLC7A11; the disease is diffuse large B-cell lymphoma.